Compare Carnival Corp (CCL) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carnival Corp vs Incyte Corporation — how do they compare? Carnival Corp trades at $27.66 (market cap $37.98B), while Incyte Corporation trades at $121.06 (market cap $24.54B). The key difference: Carnival Corp is the larger of the two by market cap, and Carnival Corp pays a 1.62% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| CCL | INCY | |
|---|---|---|
Market Cap | $37.98B | $24.54B |
Sector | Consumer Cyclical | Health |
52-Week High | $33.99 | $129.93 |
52-Week Low | $23.89 | $81.61 |
Enterprise Value | $61.91B | $20.04B |
Dividend Yield | 1.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Carnival Corporation (CCL) trades at $27.77, showing minimal daily movement with a 0.07% gain. The stock demonstrates strong fundamental recovery with revenue growing from $12.2B in 2022 to $26.6B in 2025, while net income turned positive at $2.76B. Technical indicators show bearish momentum despite neutral oscillators, with key support at $27 and resistance at $28. Recent corporate developments include new voyage bookings through 2029 and continued dividend payments of $0.15 per share.
CCL presents a compelling recovery story with improving profitability and debt reduction, though near-term technical weakness and fuel cost risks persist. Analyst consensus remains bullish with a $35.18 price target representing 27% upside potential. The stock offers exposure to the rebounding cruise industry but faces sensitivity to economic conditions and operational execution challenges.
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Carnival Corp
Carnival is the largest global cruise company, with 91 ships in its fleet in October 2022, with eight of its nine brands set to be fully redeployed by the end of 2022. Its portfolio of brands includes Carnival Cruise Lines, Holland America, Princess Cruises, and Seabourn in North America.
Read more on CCL →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
